176 related articles for article (PubMed ID: 37357717)
1. Piperacillin-Tazobactam Versus Anti-Pseudomonal Cephalosporins and Renal and Neurologic Outcomes in Critically Ill Adults: A Secondary Analysis of the SMART Trial.
Qian ET; Wang L; Stollings JL; Casey JD; Rice TW; Semler MW
J Intensive Care Med; 2023 Dec; 38(12):1127-1135. PubMed ID: 37357717
[No Abstract] [Full Text] [Related]
2. Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acute Infection: The ACORN Randomized Clinical Trial.
Qian ET; Casey JD; Wright A; Wang L; Shotwell MS; Siemann JK; Dear ML; Stollings JL; Lloyd BD; Marvi TK; Seitz KP; Nelson GE; Wright PW; Siew ED; Dennis BM; Wrenn JO; Andereck JW; Han JH; Self WH; Semler MW; Rice TW;
JAMA; 2023 Oct; 330(16):1557-1567. PubMed ID: 37837651
[TBL] [Abstract][Full Text] [Related]
3. Comparative Incidence of Acute Kidney Injury in Critically Ill Patients Receiving Vancomycin with Concomitant Piperacillin-Tazobactam or Cefepime: A Retrospective Cohort Study.
Hammond DA; Smith MN; Painter JT; Meena NK; Lusardi K
Pharmacotherapy; 2016 May; 36(5):463-71. PubMed ID: 26952639
[TBL] [Abstract][Full Text] [Related]
4. Protocol and statistical analysis plan for the Antibiotic Choice On ReNal outcomes (ACORN) randomised clinical trial.
Qian ET; Casey JD; Wright A; Wang L; Siemann J; Dear ML; Stollings J; Lloyd BD; Seitz K; Nelson G; Wright P; Siew ED; Dennis B; Wrenn J; Andereck J; Self WH; Semler MW; Rice TW;
BMJ Open; 2023 Mar; 13(3):e066995. PubMed ID: 36898748
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the risk of acute kidney injury with the use of piperacillin/tazobactam among adult critically ill patients.
Saad MO; Mohamed AM; Mitwally HA; Shible AA; Ait Hssain A; Abdelaty MA
Infection; 2020 Oct; 48(5):741-747. PubMed ID: 32700095
[TBL] [Abstract][Full Text] [Related]
6. Evaluating Renal Stress Using Pharmacokinetic Urinary Biomarker Data in Critically Ill Patients Receiving Vancomycin and/or Piperacillin-Tazobactam: A Secondary Analysis of the Multicenter Sapphire Study.
Kane-Gill SL; Ostermann M; Shi J; Joyce EL; Kellum JA
Drug Saf; 2019 Oct; 42(10):1149-1155. PubMed ID: 31240688
[TBL] [Abstract][Full Text] [Related]
7. A Large-Scale Multicenter Retrospective Study on Nephrotoxicity Associated With Empiric Broad-Spectrum Antibiotics in Critically Ill Patients.
Chen AY; Deng CY; Calvachi-Prieto P; Armengol de la Hoz MÁ; Khazi-Syed A; Chen C; Scurlock C; Becker CD; Johnson AEW; Celi LA; Dagan A
Chest; 2023 Aug; 164(2):355-368. PubMed ID: 37040818
[TBL] [Abstract][Full Text] [Related]
8. Increased Risk of Acute Kidney Injury in Critically Ill Children Treated With Vancomycin and Piperacillin/Tazobactam.
Holsen MR; Meaney CJ; Hassinger AB; Fusco NM
Pediatr Crit Care Med; 2017 Dec; 18(12):e585-e591. PubMed ID: 28906422
[TBL] [Abstract][Full Text] [Related]
9. Risk of Acute Kidney Injury in Patients on Concomitant Vancomycin and Piperacillin-Tazobactam Compared to Those on Vancomycin and Cefepime.
Navalkele B; Pogue JM; Karino S; Nishan B; Salim M; Solanki S; Pervaiz A; Tashtoush N; Shaikh H; Koppula S; Koons J; Hussain T; Perry W; Evans R; Martin ET; Mynatt RP; Murray KP; Rybak MJ; Kaye KS
Clin Infect Dis; 2017 Jan; 64(2):116-123. PubMed ID: 27986669
[TBL] [Abstract][Full Text] [Related]
10. Association of vancomycin plus piperacillin-tazobactam with early changes in creatinine versus cystatin C in critically ill adults: a prospective cohort study.
Miano TA; Hennessy S; Yang W; Dunn TG; Weisman AR; Oniyide O; Agyekum RS; Turner AP; Ittner CAG; Anderson BJ; Wilson FP; Townsend R; Reilly JP; Giannini HM; Cosgriff CV; Jones TK; Meyer NJ; Shashaty MGS
Intensive Care Med; 2022 Sep; 48(9):1144-1155. PubMed ID: 35833959
[TBL] [Abstract][Full Text] [Related]
11. Association of Acute Kidney Injury With Concomitant Vancomycin and Piperacillin/Tazobactam Treatment Among Hospitalized Children.
Downes KJ; Cowden C; Laskin BL; Huang YS; Gong W; Bryan M; Fisher BT; Goldstein SL; Zaoutis TE
JAMA Pediatr; 2017 Dec; 171(12):e173219. PubMed ID: 28973124
[TBL] [Abstract][Full Text] [Related]
12. Incidence of Acute Kidney Injury Among Critically Ill Patients With Brief Empiric Use of Antipseudomonal β-Lactams With Vancomycin.
Schreier DJ; Kashani KB; Sakhuja A; Mara KC; Tootooni MS; Personett HA; Nelson S; Rule AD; Steckelberg JM; Tande AJ; Barreto EF
Clin Infect Dis; 2019 Apr; 68(9):1456-1462. PubMed ID: 30165426
[TBL] [Abstract][Full Text] [Related]
13. Vancomycin vs. Vancomycin/Piperacillin-Tazobactam-Associated Acute Kidney Injury in Noncritically Ill Patients at a Tertiary Care Military Treatment Facility.
Anderson CW; Cazares KS; Lustik MB; Patel SM; Denunzio TM
Mil Med; 2017 Sep; 182(9):e1773-e1778. PubMed ID: 28885936
[TBL] [Abstract][Full Text] [Related]
14. Piperacillin-tazobactam dosing in anuric acute kidney injury patients receiving continuous renal replacement therapy.
Rungkitwattanakul D; Charoensareerat T; Chaichoke E; Rakamthong T; Srisang P; Pattharachayakul S; Srisawat N; Chaijamorn W
Semin Dial; 2023; 36(6):468-476. PubMed ID: 36807546
[TBL] [Abstract][Full Text] [Related]
15. Incidence of Acute Kidney Injury Among Patients Receiving the Combination of Vancomycin with Piperacillin-Tazobactam or Meropenem.
Robertson AD; Li C; Hammond DA; Dickey TA
Pharmacotherapy; 2018 Dec; 38(12):1184-1193. PubMed ID: 30175410
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of piperacillin and tazobactam in critically Ill patients treated with continuous kidney replacement therapy: A mini-review and population pharmacokinetic analysis.
Selig DJ; DeLuca JP; Chung KK; Pruskowski KA; Livezey JR; Nadeau RJ; Por ED; Akers KS
J Clin Pharm Ther; 2022 Aug; 47(8):1091-1102. PubMed ID: 35352374
[TBL] [Abstract][Full Text] [Related]
17. The Risk of Acute Kidney Injury in Critically Ill Patients Receiving Concomitant Vancomycin With Piperacillin-Tazobactam or Cefepime.
Molina KC; Barletta JF; Hall ST; Yazdani C; Huang V
J Intensive Care Med; 2020 Dec; 35(12):1434-1438. PubMed ID: 30741072
[TBL] [Abstract][Full Text] [Related]
18. Incidence and Risk Factors of Acute Kidney Injury in Patients Receiving Concomitant Vancomycin and Continuous-Infusion Piperacillin/Tazobactam: A Retrospective Cohort Study.
Blair K; Covington EW
Ann Pharmacother; 2020 Nov; 54(11):1096-1101. PubMed ID: 32406243
[TBL] [Abstract][Full Text] [Related]
19. Risk of Acute Kidney Injury and Clostridioides difficile Infection With Piperacillin/Tazobactam, Cefepime, and Meropenem With or Without Vancomycin.
Lee JD; Heintz BH; Mosher HJ; Livorsi DJ; Egge JA; Lund BC
Clin Infect Dis; 2021 Oct; 73(7):e1579-e1586. PubMed ID: 33382398
[TBL] [Abstract][Full Text] [Related]
20. Empirical carbapenems or piperacillin/tazobactam for infections in intensive care: An international retrospective cohort study.
Meier N; Munch MW; Granholm A; Perner A; Hertz FB; Venkatesh B; Hammond NE; Li Q; De Bus L; De Waele J; Kauzonas E; Sjövall F; Møller MH; Helleberg M
Acta Anaesthesiol Scand; 2024 Jul; 68(6):821-829. PubMed ID: 38549422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
